Jason S. McLellan

This study identifies key glycoprotein residues that enhance the efficacy of a CCHFV vaccine by modulating cleavage and fusogenicity in animal models.

This study isolates and characterizes monoclonal antibodies against Toscana virus's Gc glycoprotein, identifying cross-reactive antibodies that protect against Rift Valley Fever Virus.

The paper identifies gH/UL116 as a target for antibodies that neutralize HCMV and activate FcγR, showing its potential as a vaccine candidate.

This study designs prefusion-stabilized HSV-2 gB antigens using structure-based methods and evaluates their immunogenicity, finding no improvement in neutralizing antibody titers compared to postfusion constructs.

This study uses cryo-EM to analyze antibodies targeting HCMV glycoproteins, identifying synergistic combinations that enhance neutralization.

The paper identifies a broadly neutralizing antibody targeting the S2 subunit of sarbecoviruses, revealing a conserved site of vulnerability in the spike protein.

This study uses molecular dynamics simulations to analyze how mutations in the SHC014-CoV spike protein affect its structural dynamics and allosteric communication, revealing mechanisms that enhance viral entry.

The paper identifies prefusion-specific human antibodies against HSV-2 gB that neutralize both HSV-1 and HSV-2 and protect neonatal mice.

This study characterizes the DRT1 antiphage defence system, showing it generates semirandom DNA adducts that regulate filament assembly and function through structural changes.

The paper determines high-resolution structures of hantavirus glycoprotein tetramers and related complexes, revealing new insights into their organization and function, and evaluates their potential for vaccine design.

This study evaluates the resistance barrier of RSM01, a long-acting RSV monoclonal antibody, showing infrequent and moderate in vitro resistance compared to licensed mAbs.

The paper identifies a human antibody that neutralizes RSV and hMPV by targeting a novel epitope spanning multiple antigenic sites, showing cross-protection in a mouse model.

This study identifies PARP1's role in recruiting SPRTN to DPCs via PARylation, revealing a mechanism for DPC repair and degradation.

The paper identifies OPG153 as a target of broadly neutralizing antibodies against MPXV and related viruses using antigen-agnostic isolation, AlphaFold 3 modeling, and cryo-EM.

This paper engineers IgG1 antibodies with modified Fc domains to resist viral Fc receptor binding, enhancing NK cell activation and reducing HCMV spread in infected cells.

This study identifies mAbs targeting HCoV-HKU1 spike protein and shows that receptor-binding site recognition alone does not predict neutralization in primary cells.

This paper identifies an adaptive mutation in the WIV1-CoV spike protein that enhances ACE2 binding and cell entry by altering spike dynamics, suggesting alternative spillover mechanisms for bat sarbecoviruses.

This study shows that the R21/Matrix-M malaria vaccine induces specific IgG antibodies targeting multiple CSP epitopes, contributing to its efficacy against P. falciparum malaria.

This study designs and characterizes a prefusion-stabilized EBV gB antigen, showing improved immunogenicity and structural insights for vaccine development.

This study compares humoral immunity elicited by prefusion-like and postfusion forms of HCMV gB in mice, finding similar neutralization titers but differences in antibody binding and phagocytosis.

This paper defines neutralizing epitopes on pertussis toxin using cryo-EM structures and functional assays, providing insights for vaccine development.

This study identifies GP38 as a viral toxin causing vascular leak and shows that specific GP38-targeting antibodies block this effect in vitro and in vivo.

This paper introduces MAGE, a model that generates paired human antibody sequences against specific targets, validated against SARS-CoV-2, H5N1, and RSV-A.

The paper describes the structure and immunogenicity of a stabilized CCHFV heterotrimeric glycoprotein complex and shows it provides 40% protection against viral challenge in mice.

The paper investigates how SARS-like bat coronaviruses evolve enhanced receptor binding and cell entry through specific genetic substitutions.

The paper identifies a pan-betacoronavirus antibody that binds the S2 subunit of spike proteins and induces Fc-dependent antiviral responses, offering insights into non-neutralizing antibody protection.

This paper describes the stabilization of HCMV gB in a prefusion-like conformation using structure-based design and shows similar neutralizing antibody titers against postfusion and prefusion forms.

This study compares IgG antibody responses from SARS-CoV-2 infection, vaccination, and hybrid immunity, finding that hybrid immunity retains the imprint of the initial exposure and enhances antibody breadth and affinity.

The paper identifies non-neutralizing antibodies from CCHFV survivors that target multiple regions on GP38, showing protective efficacy in rodent models.

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.